ROCKVILLE, Md.--(BUSINESS WIRE)--
Emergent BioSolutions Inc. EBS today announced its decision to
expand the protocol for its ongoing Phase 1b, single arm, open label
study (Protocol 16009) evaluating the safety and efficacy of TRU-016 in
combination with rituximab in previously untreated patients with chronic
lymphocytic leukemia (CLL). The expanded protocol will include two new
study cohorts to examine a lower dose of TRU-016 with rituximab in front
line CLL and to evaluate the combination in relapsed CLL patients. This
decision is based on strong patient enrollment along with encouraging
early safety and efficacy data from this study. TRU-016 is the company's
humanized anti-CD37 monospecific protein therapeutic, built on its
ADAPTIRTM (Modular Protein Technology) platform, for the
treatment of CLL.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in